Metachromatic Leukodystrophy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of metachromatic leukodystrophy (MLD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of MLD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s MLD forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MLD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following MLD patient populations:
- Diagnosed prevalence of MLD.
- Diagnosed prevalence of MLD (late infantile).
- Diagnosed prevalence of MLD (juvenile).
- Diagnosed prevalence of MLD (adult).
Note: Coverage may vary by country.
Table of contents
- Metachromatic Leukodystrophy - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of metachromatic leukodystrophy)
- Diagnosed prevalent cases of metachromatic leukodystrophy
- Diagnosed prevalent cases of metachromatic leukodystrophy (late infantile)
- Diagnosed prevalent cases of metachromatic leukodystrophy (juvenile)
- Diagnosed prevalent cases of metachromatic leukodystrophy (adult)
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations table
Ansuman Swain, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.